0001209191-23-007494.txt : 20230207 0001209191-23-007494.hdr.sgml : 20230207 20230207160840 ACCESSION NUMBER: 0001209191-23-007494 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20230203 FILED AS OF DATE: 20230207 DATE AS OF CHANGE: 20230207 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: RENSCHLER MARKUS MD CENTRAL INDEX KEY: 0001217598 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-40499 FILM NUMBER: 23595137 MAIL ADDRESS: STREET 1: C/O PHARMACYCLICS INC STREET 2: 995 E ARQUES AVE CITY: SUNNYVALE STATE: CA ZIP: 94085-4521 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Cyteir Therapeutics, Inc. CENTRAL INDEX KEY: 0001662244 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 455429901 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 128 SPRING STREET STREET 2: BUILDING A, SUITE 510 CITY: LEXINGTON STATE: MA ZIP: 02421 BUSINESS PHONE: 857-285-4140 MAIL ADDRESS: STREET 1: 128 SPRING STREET STREET 2: BUILDING A, SUITE 510 CITY: LEXINGTON STATE: MA ZIP: 02421 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2023-02-03 0 0001662244 Cyteir Therapeutics, Inc. CYT 0001217598 RENSCHLER MARKUS MD C/O CYTEIR THERAPEUTICS, INC. 128 SPRING ST, BUILDING A, SUITE 510 LEXINGTON MA 02421 1 1 0 0 President and CEO Common Stock 2023-01-13 5 A 0 E 5000 1.49 A 983736 D Stock Option (Right to Buy) 1.69 2023-02-03 4 A 0 302600 0.00 A 2033-02-03 Common Stock 302600 302600 D The reporting person is voluntarily reporting the acquisition of the Company's common stock pursuant to the Cyteir Therapeutics, Inc. Employee Stock Purchase Program ("ESPP"), for the ESPP purchase period of July 15, 2022 through January 13, 2023. This transaction is also exempt from Rule 16b-3(c). In accordance with the ESPP, these shares were purchased based on 85% of the closing stock price January 13, 2023, the last trading day of the purchase period. The shares of common stock underlying this stock option award vest as to 2.083% in 48 equal monthly installments after the grant date, subject to the Reporting Person's continued employment with the Company through the applicable vesting date. /s/ Adam M. Veness, as attorney-in-fact for Markus Renschler, M.D. 2023-02-07